Summary by Futu AI
On February 5, 2024, Exicure, Inc., a biotechnology company known for developing nucleic acid therapies, announced a patent license agreement with Bluejay Therapeutics, Inc., a private biopharmaceutical company. The agreement grants Bluejay an exclusive license to use Exicure's patents for developing cavrotolimod as a potential treatment for hepatitis. Bluejay made an initial payment to Exicure and will also pay royalties on future net sales of any licensed technology. Exicure retains responsibility for patent maintenance and prosecution. CEO Paul Kang highlighted the partnership's alignment with Exicure's strategic shift towards maximizing shareholder value following a restructuring and suspension of clinical activities. The company is exploring strategic alternatives for its biotechnology assets.